Latest Breaking News On - Edna kaplan - Page 11 : comparemela.com

EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P.

United statesJessica breuDaniel vittEdna kaplanPaula schwartzAndreas muehlerExchange commissionImmunic incDistribution servicesRx communications groupCompletes enrollmentIts phaseVidofludimus calciumProgressive multiple sclerosisProgressive multipleUnblinded interim biomarker analysis expected

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.

United statesEdna kaplanLewish benderBristol myers squibbMichael millerMerck sharpe dohmeAngel arnaoutOntario institute of cancer researchVaccine branchDevelopment rd expensesNational cancer instituteAmerican society of clinical oncologyDevelopment agreementIntensity therapeutics incCompany on twitter intensityincPrnewswire intensity therapeutics inc

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

Webcast to be Held at 8:00 am ET on Monday, August 14, 2023 WESTPORT, Conn., Aug. 7, 2023 /PRNewswire/ Intensity Therapeutics, Inc. , a clinical-stage biotechnology company focused on the.

United statesMichael millerMerck sharpe dohmeEdna kaplanBristol myers squibbRx communications groupOntario institute of cancer researchCompany on twitter intensityincPrnewswire intensity therapeutics incOttawa hospital research instituteDevelopment agreementVaccine branchNational cancer instituteIntensity therapeutics incIntensity therapeuticsMerck sharpe

Immunic, Inc Reports Second Quarter 2023 Financial Results and Provides Corporate Update

– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective.

Paula schwartzDaniel vittJessica breuEdna kaplanVincent ossipowRichard rudickDevelopment rd expensesRx communications groupExchange commissionPrnewswire immunic incImmunic incPreclinical data publishedPotent nurrReinforcing neuroprotective potentialMultiple sclerosisPositive results from phase

EQS-News: Immunic, Inc : Immunic to Participate in Investor and Scientific Conferences in August

EQS-News: Immunic, Inc : Immunic to Participate in Investor and Scientific Conferences in August
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesJessica breuDaniel vittEdna kaplanPaula schwartzEvelyn peelenRx communications groupExchange commissionImmunic incDistribution servicesInternational congressScientific conferencesPacgrow healthcareChief executive officerSenior manager translational pharmacology